Sun Pharma Q1 Profit Rises 27% with Revenue Growth Over 10%
Sun Pharmaceutical Industries Ltd reported a 27% year-on-year rise in Q1 FY27 net profit to ₹2,895 crore, with revenue increasing over 10% to approximately ₹15,184 crore. India formulations sales grew 16%, contributing 36.1% of consolidated sales, while US formulations declined nearly 10%. EBITDA rose 2.7% to ₹4,418 crore, though the EBITDA margin contracted by 220 basis points. Expenses increased by 13.5%, partly due to acquisition and labor code costs. The company launched new products domestically and maintained its position as India's largest pharmaceutical firm.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 33/100.
Outlets measured: economictimes, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 31 Jul, 09:12 am. Other outlets followed.